Lamisil AT Spray Pump, Solution Dropper Line Extensions Launching June 1
This article was originally published in The Tan Sheet
Executive Summary
Novartis Lamisil AT Spray Pump and Solution Dropper, both terbinafine hydrochloride solution 1%, are launching June 1, "just in time for the peak summer athlete's foot season," the firm said. FDA approved the Rx-to-OTC switch March 17. Novartis filed the NDA (21-124) for the topical solution with the agency May 14, 1999.
You may also be interested in...
Lotrimin Ultra Antifungal Switch Approved By FDA
Schering-Plough's Lotrimin Ultra will launch nationwide in the first quarter of 2002, marking the third generation of OTC athlete's foot antifungals to bear the Lotrimin name
Schering-Plough Foot Care Sales Show Modest Growth; Sun Care Plummets
Schering-Plough's foot care/antifungals business stood alone as the sole producer of positive sales growth within the firm's consumer health stable during the third quarter.
Novartis
Print ads will break in July for Lamisil AT Spray Pump and Solution Dropper (terbinafine hydrochloride 1%). The line extensions shipped May 19 (1"The Tan Sheet" March 27, p. 10). TV spots broke the week of June 18, and an FSI advertising "The best way to cure athlete's foot now in a targeted spray" dropped June 25. A third new product, Odor Guard deodorant foot powder, "From the makers of Lamisil AT," will be supported with dedicated promotions and advertising in health clubs. The spray pump and dropper will each retail for $9.99, the powder for $4.99